PTC518-CNS-002-HD
A Phase 2a, Randomized, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects with Huntington’s Disease
Phase 2 study testing PTC518 in Huntington's disease.
Temporarily haltedPhase IINot specifiedCTIS (EU)Treatment trial
- EU sites are temporarily halted (CTIS (EU))
Recruiting in: Austria, France, Germany +3 more
Sponsor: PTC Therapeutics Inc.
Preparing a short plain-English summary.